http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100878137-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2003-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100878137-B1 |
| titleOfInvention | Mixtures and methods for enhanced mucosal delivery of Ｙ2 receptor-binding peptides and methods for the prevention and treatment of obesity |
| abstract | The present invention relates to pharmaceutical compositions and methods relating to at least one YY peptide mixture and one or more intranasal delivery enhancing agents for enhancing intranasal delivery of YY peptides for the treatment of various diseases and symptoms in mammalian subjects, including obesity. It is about the field. In one aspect of the invention, the intranasal delivery formulations and methods allow for enhanced delivery of the YY peptide to plasma or central nervous system (CNS) tissue or body fluids. For example, the highest concentration of YY peptide (C max ) in the subject's plasma or CNS tissue or body fluid is determined by the subject's plasma or CNS following administration of the same concentration of PYY peptide or subcutaneous injection of PYY peptide. 20% or more when compared to the highest YY peptide concentration in tissue or body fluid. |
| priorityDate | 2002-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1387.